Pentasa and platelet count decreased Patient Reports February 13, 2012

Pentasa Side Effects Report #4704544-4
Pentasa side effect was reported by a Health Professional from on June 16, 2005. Female patient, 79 years of age, was diagnosed with crohn's disease  and was treated with Pentasa. After drug was administered, patient experienced the following side effects: jaundice , platelet count decreased. Pentasa dosage: 1.5 MG DAILY ORAL. During the same period patient was treated with TICLOPIDINE. Patient was hospitalized. Patient recovered.

Pentasa Side Effects Report #4726397-0
Pentasa side effect was reported by a Consumer or non-health professional from JAPAN on July 12, 2005. Female patient, 79 years of age, was diagnosed with crohn's disease  and was treated with Pentasa. After drug was administered, patient experienced the following side effects: jaundice , platelet count decreased. Pentasa dosage: unknown. During the same period patient was treated with TICLOPIDINE. Patient was hospitalized. Patient died.

Pentasa Side Effects Report #4778925-7
Pentasa side effect was reported by a Consumer or non-health professional from JAPAN on Sept 08, 2005. Female patient, 78 years of age, was diagnosed with crohn's disease  and was treated with Pentasa. After drug was administered, patient experienced the following side effects: hepatic failure, jaundice , liver disorder, platelet count decreased. Pentasa dosage: unknown. Patient died on 06/13/2005.

Pentasa Side Effects Report #4788883-7
Pentasa side effect was reported by a Health Professional from JAPAN on Sept 21, 2005. Female patient, 78 years of age, was diagnosed with crohn's disease , arteriosclerosis obliterans and was treated with Pentasa. After drug was administered, patient experienced the following side effects: colonic polyp , crohn's disease , hepatic failure, hyperparathyroidism, hypertension, jaundice , liver disorder, platelet count decreased, renal failure chronic. Pentasa dosage: unknown. During the same period patient was treated with TICLOPIDINE, OMEPRAZOLE. Patient died on 06/13/2005.


Pentasa Side Effects Report #5065263-0
Pentasa side effect was reported by a Consumer or non-health professional from DENMARK on June 16, 2005. Male patient, 32 years of age, was diagnosed with crohn's disease  and was treated with Pentasa. After drug was administered, patient experienced the following side effects: platelet count decreased, white blood cell count decreased. Pentasa dosage: 1500 MG DAILY, ORAL. During the same period patient was treated with AZATHIOPRINE. Patient recovered.

Pentasa Side Effects Report #4614148-X
Pentasa side effect was reported by a Health Professional from on Mar 01, 2005. Male patient, 23 years of age, was diagnosed with crohn's disease  and was treated with Pentasa. After drug was administered, patient experienced the following side effects: crohn's disease , disease recurrence, haemoglobin decreased, leukopenia, platelet count decreased. Pentasa dosage: 750 MG, 3X/DAY; TID, ORAL. During the same period patient was treated with MERCAPTOPURINE. Patient was hospitalized. Patient recovered.

Pentasa Side Effects Report #4627936-0
Pentasa side effect was reported by a Consumer or non-health professional from on Mar 18, 2005. Male patient, 23 years of age, was diagnosed with crohn's disease  and was treated with Pentasa. After drug was administered, patient experienced the following side effects: haemoglobin decreased, leukopenia, platelet count decreased, proctalgia, pyrexia. Pentasa dosage: unknown. During the same period patient was treated with MERCAPTOPURINE, LEVOFLOXACIN. Patient was hospitalized. Patient recovered.

Pentasa Side Effects Report #5199851-8
Pentasa side effect was reported by a Consumer or non-health professional from FRANCE on Dec 15, 2006. Male patient, 77 years of age, was diagnosed with colitis ulcerative and was treated with Pentasa. After drug was administered, patient experienced the following side effects: brain natriuretic peptide increased, c-reactive protein increased, dyspnoea exertional, fibrin d dimer increased, intracardiac mass, intracardiac thrombus, pericardial effusion, platelet count decreased, treatment noncompliance. Pentasa dosage: 2000 MG DAILY, ORAL. During the same period patient was treated with RAMIPRIL, BISOPROLOL, AMLODIPINE BESYLATE, FUROSEMIDE, LANSOPRAZOLE, ALENDRONATE, ACETYLSLICYLATE LYSINE, PREDNISOLONE SULFOBENZOATE. Patient was hospitalized. Patient recovered.